Assuntos
Dermatoses Faciais/diagnóstico , Hipopigmentação/diagnóstico , Pescoço , Neoplasias de Anexos e de Apêndices Cutâneos/diagnóstico , Neoplasias de Anexos e de Apêndices Cutâneos/patologia , Neoplasias Cutâneas/diagnóstico , Adulto , Biópsia , Diagnóstico Diferencial , Dermatoses Faciais/patologia , Humanos , Hipopigmentação/patologia , Masculino , Pele/patologia , Neoplasias Cutâneas/patologiaAssuntos
Inibidores da Angiogênese/efeitos adversos , Cicatriz/patologia , Neoplasias Colorretais/tratamento farmacológico , Proteínas Recombinantes de Fusão/efeitos adversos , Úlcera Cutânea/induzido quimicamente , Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores , Abdome , Inibidores da Angiogênese/uso terapêutico , Bandagens , Neoplasias Colorretais/cirurgia , Humanos , Masculino , Pessoa de Meia-Idade , Necrose/induzido quimicamente , Receptores de Fatores de Crescimento do Endotélio Vascular/uso terapêutico , Proteínas Recombinantes de Fusão/uso terapêutico , Recidiva , Remissão Espontânea , Úlcera Cutânea/patologia , Úlcera Cutânea/terapia , Suspensão de TratamentoRESUMO
Locoregional cutaneous metastases of melanoma (LCMM) represent a therapeutic challenge. Many treatment options are available with varying results. The combination of cryotherapy and imiquimod, two treatments with a possible synergistic effect, has not yet been described for treating this disease. In this paper, we aimed to show the response of LCMM to cryotherapy combined with topical imiquimod 5%. A retrospective review of 20 patients diagnosed with LCMM and treated with cryotherapy combined with topical imiquimod 5% between November 2000 and May 2014 at three institutions was performed. The locoregional cutaneous response was evaluated. After a mean of five sessions, 13 patients (65%) responded to treatment, eight (40%) of these completely and five (25%) partially. Systemic disease progressed in 16 (80%) patients. Cryotherapy followed by topical imiquimod 5% is simple to apply, has minimal adverse effects and provides response rates similar to other, more complex treatment options.
Assuntos
Aminoquinolinas/uso terapêutico , Antineoplásicos/uso terapêutico , Criocirurgia , Melanoma/terapia , Neoplasias Cutâneas/terapia , Administração Cutânea , Idoso , Idoso de 80 Anos ou mais , Aminoquinolinas/administração & dosagem , Antineoplásicos/administração & dosagem , Terapia Combinada , Feminino , Humanos , Imiquimode , Masculino , Melanoma/tratamento farmacológico , Melanoma/patologia , Melanoma/cirurgia , Pessoa de Meia-Idade , Metástase Neoplásica , Estudos Retrospectivos , Neoplasias Cutâneas/tratamento farmacológico , Neoplasias Cutâneas/patologia , Neoplasias Cutâneas/cirurgiaRESUMO
BACKGROUND: Treatment of oral erosive lichen planus is considered a therapeutic challenge. Various systemic and topical agents aimed at controlling the symptoms, rather than curing the lesions, have been used with varying results. OBJECTIVE: To evaluate the response to treatment with antimalarial drugs in patients with oral erosive lichen planus. METHODS: Eight patients diagnosed with oral erosive lichen planus were treated with antimalarial agents. The first clinical evaluation was made after a month of treatment and then every 2-3 months. Baseline ophthalmologic examinations were performed, and laboratory values were monitored before and during treatment. RESULTS: All studied patients who had previously been resistant to other treatments responded favorably. Pain relief and reduced erythema and erosions were observed after of a mean of 2.4 months. CONCLUSION: Antimalarials may be useful for the treatment of oral erosive lichen planus. They are easily administered and affordable, with few adverse effects.
